LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

Search

Guardant Health Inc

Fermé

SecteurSoins de santé

93.98 -4.02

Résumé

Variation du prix de l'action

24h

Actuel

Min

93.29

Max

97.92

Chiffres clés

By Trading Economics

Revenu

7.2M

-93M

Ventes

33M

265M

Marge bénéficiaire

-34.965

Employés

1,999

EBITDA

6.6M

-82M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

-10.06% downside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

3.3B

12B

Ouverture précédente

98

Clôture précédente

93.98

Sentiment de l'Actualité

By Acuity

50%

50%

171 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Guardant Health Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 nov. 2025, 21:34 UTC

Résultats

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13 nov. 2025, 23:45 UTC

Market Talk

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13 nov. 2025, 23:42 UTC

Acquisitions, Fusions, Rachats

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13 nov. 2025, 23:41 UTC

Market Talk

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13 nov. 2025, 23:24 UTC

Résultats

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13 nov. 2025, 23:24 UTC

Résultats

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13 nov. 2025, 23:23 UTC

Résultats

JBS NV 3Q EPS 52c >JBS

13 nov. 2025, 23:23 UTC

Résultats

JBS NV 3Q Sales $22.6B >JBS

13 nov. 2025, 23:04 UTC

Market Talk

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13 nov. 2025, 22:02 UTC

Résultats

Nu Holdings 3Q Net $783M >NU

13 nov. 2025, 22:01 UTC

Résultats

Nu Holdings 3Q Rev $4.2B >NU

13 nov. 2025, 21:51 UTC

Acquisitions, Fusions, Rachats

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13 nov. 2025, 21:50 UTC

Résultats

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13 nov. 2025, 21:45 UTC

Acquisitions, Fusions, Rachats

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13 nov. 2025, 21:41 UTC

Acquisitions, Fusions, Rachats

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13 nov. 2025, 21:36 UTC

Acquisitions, Fusions, Rachats

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13 nov. 2025, 21:36 UTC

Acquisitions, Fusions, Rachats

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13 nov. 2025, 21:36 UTC

Acquisitions, Fusions, Rachats

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13 nov. 2025, 21:36 UTC

Acquisitions, Fusions, Rachats

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13 nov. 2025, 21:36 UTC

Acquisitions, Fusions, Rachats

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13 nov. 2025, 21:33 UTC

Market Talk

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13 nov. 2025, 21:33 UTC

Résultats

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13 nov. 2025, 21:31 UTC

Résultats

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13 nov. 2025, 21:25 UTC

Résultats

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13 nov. 2025, 21:25 UTC

Résultats

Figure Tech Solutions 3Q EPS 34c >FIGR

13 nov. 2025, 21:23 UTC

Résultats

Intchains Group 3Q Rev $1.3M >ICG

13 nov. 2025, 21:03 UTC

Résultats

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13 nov. 2025, 21:02 UTC

Résultats

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13 nov. 2025, 21:01 UTC

Résultats

Applied Materials 4Q Rev $6.8B >AMAT

13 nov. 2025, 21:01 UTC

Résultats

Applied Materials 4Q Gross Margin 48.0% >AMAT

Comparaison

Variation de prix

Guardant Health Inc prévision

Objectif de Prix

By TipRanks

-10.06% baisse

Prévisions sur 12 Mois

Moyen 88 USD  -10.06%

Haut 120 USD

Bas 60 USD

Basé sur 21 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

21 ratings

21

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

38.86 / 47.41Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

171 / 374Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat